The association of hypercholesterolemia to platelet activation in CVD patients has been established [91,111] and, in this context, increased levels of PCSK9 may be responsible for platelet activation because of the impairment of lipoprotein clearance and the regulatory effects on platelets by native LDL and oxLDL. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.